The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

• Status: Not yet recruiting
• Trial end date: 2026-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is more effective in preventing adverse LV remodeling for patients with ST-elevation myocardial infarction (STEMI) than enalapril.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: West China Hospital
• Treatments: Enalapril; LCZ 696; Sacubitril and valsartan sodium hydrate drug combination; Valsartan

Criteria

Inclusion Criteria:

• Aged between 18 - 75 years old

• First-time ST-segment elevation myocardial infarction based on the newest ESC guidelines

• Timely primary percutaneous coronary intervention within 12 hours from onset

• Written informed consent acquired

Exclusion Criteria:

• Known history of or persistent clinical chronic heart failure prior to randomization

• Previous use of ARNI, or intolerance or contraindications to study drugs including ARNI or ACEI

• History of significant chronic coronary obstruction and adverse ventricular remodeling

• History of any cardiomyopathy, valvular heart disease, congenital heart disease, stent or CABG, or planned open-heart surgery within 3 months

• History of hepatic impairment or history of cirrhosis with evidence of portal hypertension

• History of chronic renal dysfunction, or eGFR < 30 ml/min/1.73 m2

• History of malignancy and with a life span less than one year

• Patients with a known history of angioedema related to previous ACEIs/ARB therapy.

• With contraindication to MRI examination (pacemaker and claustrophobia) or cannot finish breath-holding when lying on the examination bed

• Pregnancy or nursing women